Abstract

A REVIEW ON THE ROLE OF REMDESIVIR FOR THE TREATMENT OF COVID 19

Pranith P. L.*, Amitha Mary Samson, E. Sam Jeeva Kumar and Prasobh G. R.

.

Abstract

Severe acute respiratory coronavirus-2 (SARS-CoV-2) is an RNA virus is responsible for the greatest public health challenges of our lifetime the coronavirus disease 2019 (COVID-19) pandemic. The term coronaviruses were given based on the morphology as spherical virions with a core shell and surface projections resembling a solar corona. Alpha-, beta-, gamma-and delta coronaviruses are the four subfamilies. The incubation period of five days 7 and a median incubation period of 3 days. The clinical signs of SARS‐CoV‐2‐related disease COVID‐19 which allowed case detection was pneumonia and gastrointestinal symptoms and asymptomatic infections, especially among young children. The search for effective therapies has become a worldwide priority because of the complicated postinfection sequelae and grave consequences. Several studies have showed that remdesivir an antiviral agent is useful in treatment of COVID 19. In United States through an emergency use authorization. Along with data obtained from clinical trials on the safety profile of remdesivir against Ebola virus and information obtained from in vitro studies and animal models support remdesivir as a promising agent against SARS-CoV-2. The main intention of this study is to produce a comprehensive review of the role, Pharmacology, mechanism of action, safety of remdesivir in treatment of COVID 19.

Keywords: Antiviral, Remdesivir, Coronavirus, RNA Virus.